Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Thousands of duloxetine bottles, an antidepressant sold
Duloxetine antidepressant recalled over presence of toxic chemical
Some bottles of the antidepressant duloxetine, sold under the brand name Cymbalta, were recalled due to the presence of a toxic chemical.
FDA Has Recalled Thousands of Bottles of Antidepressant Duloxetine, Sold Under Brand Name Cymbalta: Here’s Why
The Duloxetine Delayed-Release Capsules' voluntary recall began on Oct. 10 after the FDA deemed the medication the second-highest risk classification. Over 7,100 bottles of Duloxetine were recalled, including 500 delayed-release 20mg capsules. The lot number is 220128, and the expiration date is 12/2024, per the FDA report.
FDA Recalls Thousands Of Duloxetine Antidepressant Bottles | Here's Why
The US Food and Drug Administration has recalled thousands of bottles of Duloxetine antidepressant, saying it contained high levels of a cancer-causing chemical. The federal agency has reportedly upgraded the level of risk.
7,100 bottles of antidepressant recalled by FDA now in 2nd highest risk class
Duloxetine Delayed-Release Capsules were recalled because the pills may contain high levels of a cancer-causing chemical.
Antidepressant recalled: 2nd-highest FDA risk level; drug contains cancerous chemical
The U.S. Food and Drug Administration updated the risk level of a recalled antidepressant due to the product containing high levels of a cancer-causing chemical.
FDA issues recall for antidepressant drug
Thousands of New Yorkers may have to check their medicine cabinets; the Federal Drug Administration has issued a recall for a common medicine used to treat depression the agency
Antidepressant recall: FDA upgrades risk level due to cancer-causing chemical
Now, the FDA is assigning the second-highest risk level to the recall of Duloxetine Delayed-Release Capsules, produced by Towa Pharmaceutical Europe, according to agency records and reported by SILive.com sister site NJ.com. Duloxetine is used to treat depression, anxiety and nerve pain caused by fibromyalgia.
Antidepressant recall: FDA upgrades medication risk class to 2nd highest level in recall update
The U.S. Food and Drug Administration is urging patients not to stop taking their prescribed medication if it falls under the recall but instead to address any concerns and other potential treatment o
Nationwide Antidepressant Recall Update As FDA Sets Risk Class
On October 11, the recall was classified as a class II recall by the FDA—a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote."
1h
This antidepressant is being recalled: Here’s why
The U.S. Food and Drug Administration (FDA) has issued a nationwide recall of thousands of bottles of antidepressants. These ...
Medscape
3d
Duloxetine: A Balanced and Selective Norepinephrine and Serotonin-Reuptake Inhibitor
Purpose: The pharmacology, pharmacokinetics, efficacy, safety, drug interactions, dosage and administration, cost, and place in therapy of
duloxetine
for major depression, pain from diabetic ...
Mercury News
17h
California News
In the first days of standard time, sunrise in the Bay Area will be around ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Trending now
Linked to E. coli outbreak
Arlington visit records order
Arrested in trafficking case
MO court upholds release
Lake Erie toxic algae study
Trespassing charge upheld
To close 150 locations
Veteran film producer dies
2 US troops injured in raid
To appear on Rogan podcast
FDA approves RSV vaccine
DOJ alleges racial bias
Giant ‘ghost’ fish spotted
GA election rules appeal
FAA finalizes safety rules
Brain stimulation study
Six indicted for fraud in Ohio
2025 Medicare changes
Raises US growth forecast
Infant mortality increased
SK mulls arms for Ukraine
Same-day pharmacy delivery
US semiconductor tax credit
Target to cut prices
Probing leak of US intel
Hospitals' IV fluid shortage
Ordered to hand over assets
Right whale population rises
Reveals 2025 tax brackets
To headline 2 Harris rallies
Related topics
Food and Drug Administration
Cymbalta
Feedback